MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. MedImmune is headquartered in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and Mountain View, Calif.

MedImmune’s SYNAGIS therapeutic is an FDA-approved prescription injection of antibodies that is given monthly to help protect high-risk infants from severe respiratory syncytial virus, or RSV.

RSV is a common virus that, like the flu, is seasonal and easily spread. Most children will get RSV by the age of two. RSV begins with cold-like symptoms but can spread to the lungs. For babies with certain health conditions, RSV can be very serious.

SYNAGIS is the first monoclonal antibody approved for the prevention of an infectious disease, as well as the first such drug to be safely used in children.